Sonida Senior Living

Recent news

• Rating change
  Cantor Fitzgerald Maintains Sonida Senior Living(SNDA.US) With Buy Rating, Raises Target Price to $42
  Market Newswire · 2026/5/13
• Rating change
  RBC Capital Maintains Sonida Senior Living(SNDA.US) With Buy Rating, Raises Target Price to $48
  Market Newswire · 2026/6/29
• Rating change
  Morgan Stanley Maintains Sonida Senior Living(SNDA.US) With Hold Rating, Maintains Target Price $38
  Market Newswire · 2026/5/29
• Rating change
  Citizens JMP Initiates Sonida Senior Living(SNDA.US) With Buy Rating, Announces Target Price $50
  Market Newswire · 2026/7/27
• Rating change
  Morgan Stanley Maintains Sonida Senior Living(SNDA.US) With Hold Rating, Raises Target Price to $38
  Market Newswire · 2026/5/29
• Sonida Senior Living(SNDA.US) 10% Shareholder Sells US$4.76 Million in Common Stock
  Market Newswire · 2026/9/2
• Company notice
  Otsuka Holdings: Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI
  JPX · 2025/9/22
• Pharming Announces U.S. FDA Acceptance and Priority Review of SNDA for Lower Doses of Joenja to Treat Children With APDS
  GlobeNewswire · 2026/9/25
• Rating change
  Compass Point Initiates Sonida Senior Living(SNDA.US) With Buy Rating, Announces Target Price $65
  Market Newswire · 2026/8/11
• Morgan Stanley Maintains Sonida Senior Living(SNDA.US) With Hold Rating, Maintains Target Price $44
  Market Newswire · 2026/9/1
• Rating change
  RBC Capital Maintains Sonida Senior Living(SNDA.US) With Buy Rating, Maintains Target Price $48
  Market Newswire · 2026/8/11
• Company notice
  Otsuka Holdings: Otsuka Pharmaceutical Co. and Lundbeck have announced that the FDA has approved the SNDa application for the combination of brexpiprazole and sertraline for the treatment of PTSD in adults.
  JPX · 2024/6/25
• Rating change
  Morgan Stanley Maintains Sonida Senior Living(SNDA.US) With Hold Rating, Raises Target Price to $44
  Market Newswire · 2026/9/1
• Rating change
  Cantor Fitzgerald Maintains Sonida Senior Living(SNDA.US) With Buy Rating, Raises Target Price to $47
  Market Newswire · 2026/8/11
• Company notice
  HENLIUS-B: VOLUNTARY ANNOUNCEMENT - SUPPLEMENTAL NEW DRUG APPLICATION (sNDA)FOR PRODUCTION SITE CHANGE, PRODUCTION PROCESSOPTIMIZATION AND PRODUCTION SCALE EXPANSION OFDRUG PRODUCT ETC. OF HANQUYOU (TRASTUZUMAB INJECTION)BEING APPROVED BY THE NATIONAL
  HKEX · 2022/5/17
• Company notice
  BeiGene, Ltd.: INSIDE INFORMATION - BEIGENE ANNOUNCES PDUFA GOAL DATE EXTENSION FORU.S. SNDA FOR BRUKINSA FOR THE TREATMENT OF CLL/SLL
  HKEX · 2022/6/13
• Bayer: U.S. FDA Accepts SNDA, Grants Priority Review to Lynkuet as New Indication for Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer BAYN.XE
  Dow Jones · 2026/9/28
• Company notice
  Otsuka Holdings: Otsuka and Lundbeck Announce U.S. FDA Approval of sNDA for REXULTI for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
  JPX · 2023/5/11
• Rating change
  RBC Capital Initiates Sonida Senior Living(SNDA.US) With Buy Rating, Announces Target Price $48
  Market Newswire · 2026/8/13
• Baird Upgrades Sonida Senior Living(SNDA.US) to Buy Rating, Raises Target Price to $43
  Market Newswire · 2026/9/4

Headlines are aggregated automatically and are not independently verified or edited by our team.